ProModRx adds infrastructure and capabilities that strengthen D2’s support from initial access through ongoing patient servicesSaint Charles, Mo., April 16, 2026 – D2 Solutions, a healthcare ...
Strategic acquisition marks the first step in Panthera’s European expansion, strengthening its global competitiveness Panthera Biopartners (Panthera), the leading UK based clinical trial Site ...
Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the ...
Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, ...
TauRx today announced results from a confirmatory study evaluating hydromethylthionine mesylate in participants with mild cognitive impairment and mild to moderate dementia due to Alzheimer’s disease ...
Speech could be a key clinical marker in neurodegenerative disease drug trials, says leading biotech
SynaptixBio, the only company licensed to commercialise a treatment for the rare, deadly disease H-ABC, says families value the ability to communicate more than other disease impactsSpeech is rapidly ...
New controlled cleaning and sterilization service supports biopharma customers with ready-to-use single-use assembliesKAISERSLAUTERN, Germany, April 20, 2026 / Biotech Newswire / -- Freudenberg ...
Real-world evidence is increasingly demonstrating tobacco harm reduction (THR) in action, so why do many public health bodies and regulators remain sceptical? Joe Thompson, Group Science & Regulatory ...
A study led by Karl Landsteiner University shows that the disease affects whole-brain communication networks, and that this may help predict survival.Krems, Austria, 21 April 2026 – Glioblastoma, the ...
Study of CAL101, which targets a novel upstream pathway implicated in fibrotic disease, enrolls 161 patients more than six months ahead of plan; topline data expected Q1 2027Drug candidate, a ...
The custom antibody market is projected to grow at a CAGR of approximately 10% throughout the forecast period. This expansion is driven by increasing R&D activity, rising demand for highly specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results